Findings

What do systematic reviews say?

4 questions · 4 findings · 2 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 50%High 2 · 50%

Serious adverse events · people with chronic gout

Allopurinol showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Allopurinol for chronic gout 2014 · Cochrane Headline outcomes only
RR 1.93 [0.48, 7.8]
2 studies · 453 participants
Moderate

Serious adverse events · people with chronic gout

Febuxostat 40 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (high certainty).

1 finding from 1 review

Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
RR 0.61 [0.35, 1.07]
1 study · 1513 participants
High

Serious adverse events · people with chronic gout

Febuxostat 80 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (moderate certainty).

1 finding from 1 review

Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
RR 0.91 [0.34, 2.4]
3 studies · 1044 participants
Moderate

Serious adverse events · people with chronic gout

Febuxostat 120 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (high certainty).

1 finding from 1 review

Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
RR 1.2 [0.7, 1.93]
3 studies · 1041 participants
High